GH Research is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
Employees: 11-50
Total raised: $125M
Founded date: 2018
Investors 2
| Date | Name | Website |
| 17.08.2021 | Logos Capi... | logoscapit... |
| - | RA Capital... | racap.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.04.2021 | Series B | $125M | - |
Mentions in press and media 6
| Date | Title | Description |
| 04.02.2025 | GH Research Announces Pricing of $150 Million Public Offering | DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced ... |
| 24.06.2021 | GH Research PLC Announces Pricing of Initial Public Offering | |
| 14.04.2021 | Dublin's GH Research picks up $125M Series B | GH Research, a developer of therapies to manage mental illness, has raised $125 million in a round co-led by RA Capital and RTW Investments, with participation from BVF Partners and other investors. GH Research will use the Series B capital... |
| 12.04.2021 | GH Research Closes $125M Series B Financing | GH Research Ireland Ltd, a Dublin, Ireland-based clinical-stage biopharmaceutical company, closed a $125m Series B financing. The round was co-led by RA Capital and RTW Investments, LP, with participation from existing investor BVF Partners... |
| 12.04.2021 | GH Research Announces Closing of $125 Million Oversubscribed Series B Financing | |
| 19.11.2020 | GH Research Ltd. Announces Completion of Phase 1 Clinical Study with GH001 (5-Methoxy-N,N-Dimethyltryptamine) in Healthy Volunteers and Updates on Further Progress |